Activity endpoints reported in soft tissue sarcoma phase II trials: quality of reported endpoints and correlation with overall survival.

Despite extensive research over the past 3 decades, few investigational drugs are considered as promising and these drugs failed to improve overall survival. Therefore we performed a systematic review of the literature to improve our understanding of the reasons that explain these failures.